Researchers from University of California San Diego have identified changes in the metabolic activity of the gut microbiome associated with exceptional longevity in humans and found that amplifying the same activity with engineered bacteria improved metabolic health in aged mice. The study, published on Nov. 16, 2026 in the journal Cell Metabolism, suggests that some changes in the gut microbiome that occur with aging may be protective adaptations rather than signs of decline — and could potentially be harnessed to support healthier aging.

pexels-j-kaur-1648715977-28316047

“Many studies of aging focus on what goes wrong as we get older, but our findings suggest that some changes in the gut microbiome may actually represent the body’s attempt to preserve metabolic health,” said senior author Amir Zarrinpar, MD, PhD, Stuart and Barbara L. Brody Endowed Chair in Circadian Biology and Medicine, and professor of medicine at UC San Diego School of Medicine. “If we can identify those beneficial functions and safely strengthen them, we may eventually be able to develop new ways to promote healthier aging.”

The gut microbiome — the community of bacteria and other microbes living in the digestive tract — changes throughout life and plays an important role in metabolism, inflammation and other aspects of health. Previous research has linked age-related changes in the microbiome with frailty, chronic inflammation and disease, while other studies have found distinctive microbiome features among people who age exceptionally well.

In the new study, researchers focused on how gut microbes modify bile acids, substances produced by the liver that help digest fats but also act as signaling molecules throughout the body. Gut bacteria produce enzymes called bile salt hydrolases (BSH) that chemically modify bile acids, allowing them to influence pathways involved in metabolism, inflammation and the body’s internal clock.

Young and old

The researchers first studied young and aged mice and found that aging was associated with increased microbial activity related to BSH and greater bile acid modification. To determine whether a similar pattern occurred in humans, they reanalyzed publicly available data from a human aging cohort. The analysis included bile acid measurements from 48 young adults, 107 older adults and 125 centenarians. The centenarian group showed higher ratios of certain modified bile acids than both younger groups. Analysis of microbiome data also found greater abundance of a gene associated with BSH activity among centenarians compared with the older adult group.

The researchers then asked whether enhancing this microbial function could produce health benefits. They engineered a strain of bacteria native to the gut to continuously produce BSH and introduced it into 82-week-old mice — considered aged. A single treatment resulted in stable colonization, allowing the bacteria to persist and produce the enzyme over time.

Approximately 20 weeks after treatment, mice receiving the BSH-producing bacteria had significantly improved insulin sensitivity and modestly improved glucose tolerance compared with mice receiving a matched control bacterium. By 32 weeks, the treated mice also showed changes consistent with lower body weight and fat mass and greater lean mass. Other findings pointed to increased use of fat for energy, improved mitochondrial function and changes in gene activity related to inflammation and the body’s internal clock.

What it means

The results do not show that the microbial changes caused exceptional longevity in humans or that the engineered bacteria can extend lifespan. The authors note that centenarians and aged mice are not directly comparable, and the human findings provide supporting rather than definitive evidence. More studies in people will be needed to determine whether increased BSH activity is a marker of healthy aging, a contributor to it, or both.

The study also points toward a broader possibility: rather than attempting to replace the entire gut microbiome, researchers may eventually be able to identify beneficial microbial functions and selectively enhance them. Future studies will investigate how different forms of BSH affect bile acid metabolism, inflammation, energy use and other aspects of aging, as well as whether the approach works similarly in females, given established differences in aging based on sex.

“The goal isn’t simply to live longer — it’s to understand the biology that allows some people to remain resilient as they age,” said Zarrinpar. “The microbiome gives us an intriguing opportunity because, unlike many aspects of aging, it may be something we can modify. This study gives us a starting point for asking whether beneficial microbial functions can be amplified to help preserve metabolic health later in life.”

Study background

Additional co-authors on the study include: Ana Carolina Dantas Machado, Wuling Zhong, Anand R. Saran, Baylee J. Russell, Erica Maissy, Stephany Flores-Ramos, Juan Pablo Zuniga-Hertz, R. Alexander Richter, Max W. Chang, Alan Saltiel and Hemal Patel from UC San Diego School of Medicine. Rob Knight from UC San Diego School of Medicine and Jacobs School of Engineering. April L. Lukowski from Scripps Institution of Oceanography and Skaggs School of Pharmacy and Pharmaceutical Sciences. Antonio F.M. Pinto and Alan Saghatelian from the Salk Institute for Biological Studies. Koji Atarashi and Kenya Honda from Keio University. 

MICROBIOLOGY NEWS: Register with The Microbiologist for more free articles  

Machado is supported by National Institutes of Health grant #R01 HL148801-02S1. Zhong is supported by the Larry L. Hillblom Foundation (2025-D-188-FEL). Maissy is supported by NIH grant #F31 HD106762. Saltiel is supported by the Glenn Foundation for Medical Research Postdoctoral Fellowships in Aging Research. Zarrinpar is supported by AFAR Research Grant for Junior Faculty, VA Merit Award #I01 RD001332, and NIH awards R21 MH117780, R21AI194932, R01 EB030134, R01 AI163483, R01 CA310170, and U01 CA265719. Patel  is supported by a VA Research Career Scientist Award (BX005229). All authors receive institutional support from NIH P30 DK120515, P30 DK063491, P30 CA014195, and UL1 TR001442.

Zarrinpar is a co-founder and equity-holder in Endure Biotherapeutics. Knight is a scientific advisory board member and consultant for BiomeSense, Inc., has equity and receives income. Knight is a scientific advisory board member and has equity in GenCirq. Knight has equity in and acts as a consultant for Cybele. The terms of these arrangements have been reviewed and approved by University of California San Diego in accordance with its conflict of interest policies. No disclosures were reported by the other authors.